MedTrace Logo

Muscle Recovery After Omega-3 Supplementation

NCT07237113 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-11-19

No results posted yet for this study

Summary

In recent decades, omega-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been proposed as potential therapeutic agents for minimizing muscle damage induced by eccentric exercise, especially when supplementation is long-term (\> 6 weeks) and at high doses (\> 1 g/d). However, no study has analyzed whether these effects are mediated by an increase in oxylipins (metabolites derived from EPA and DHA), which play an essential role in the muscle regeneration process. The objective of the present study is to determine the effect of eight weeks of high-dose omega-3 fatty acid supplementation on blood oxylipin levels and their association with muscle function and markers of muscle damage after high-intensity eccentric exercise in young men.

Conditions

  • Damage Muscle

Interventions

DIETARY_SUPPLEMENT

Placebo

The participants will be supplemented with 5 capsules per day of a placebo-filled gelatin capsule for 8 weeks.

DIETARY_SUPPLEMENT

Omega

The participants will be supplemented with 5 capsules per day of Omega UP (Newscience, Chile), equivalent to 2.5 g/d of DHA and 0.5 g/d of EPA for 8 weeks

Sponsors & Collaborators

  • Universidad Nacional Andres Bello

    collaborator OTHER

  • University of Manitoba

    collaborator OTHER

  • Instituto de Ciencias de la Salud, Universidad de O'Higgins

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2023-09-01
Completion
2024-09-01

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07237113 on ClinicalTrials.gov